IXICO plc IXICO awarded significant long-term contract (3807X)

TIDMIXI

RNS Number : 3807X

IXICO plc

28 August 2015

IXICO awarded significant long-term contract with leading global pharmaceutical company

Highlights IXICO's position as partner of choice for major pharmaceutical companies in neurodegeneration drug development

IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that it has been awarded a long-term contract from a leading global pharmaceutical company with a revenue value to IXICO of c. $1 million per year.

This project is for a large Phase II/III global clinical study in neurodegenerative disease which is expected to run over at least 7 years and will utilise IXICO's expertise in the collection and manipulation of magnetic resonance imaging (MRI) data including data from advanced MRI techniques. IXICO will be working with specialist imaging centres at multiple global sites and will be using its TrialTracker(R) and Assessa(R) digital platforms to collect imaging data and measure and monitor changes in disease pathology in subjects enrolled in the study.

"This important project award highlight's IXICO's growing position in the neuroscience clinical trial market," said John Hall, SVP Commercial Operations. "Our image data management system, TrialTracker(R), is recognised as a leading platform to support the management of sites and imaging data in global clinical trials involving 10,000s of data sets. Furthermore, IXICO is being increasingly valued as a collaborative partner in the execution of such projects, where, through its scientific expertise and digital health platforms such as Assessa(R), IXICO is providing further value to the customer."

Professor Derek Hill, Chief Executive Officer of IXICO, commented: "We are very pleased to have been awarded this significant project which recognises our expertise and utilises our digital technology platforms. This long-term contract with a valued customer coupled with our other previously announced new wins provides strong foundations for our growing business."

Enquiries:

 
 IXICO plc                           +44 20 3763 7499 
 Derek Hill, CEO 
 Susan Lowther, CFO 
 Charles Spicer, VP Corporate 
  Development 
 
 Peel Hunt LLP (Nominated Adviser 
  and Broker)                        +44 20 7418 8900 
 James Steel 
 Oliver Jackson 
 
 Daniel Stewart & Company (Joint 
  Broker)                            +44 207 776 6550 
 Martin Lampshire 
 David Coffman 
 
 FTI Consulting Limited (Investor 
  Relations)                         +44 20 3727 1000 
 Simon Conway 
 Matthew Moss 
  Mo Noonan

Notes to Editors

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital health technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including Alzheimer's disease, Huntington's disease, other causes of dementia and Multiple Sclerosis.

Assessa(R)

IXICO's digital platform technology which can combine imaging, demographic, cognitive and functional information to improve the precision of patient stratification, differential diagnosis and predict likely disease progression of dementia and other neurodegenerative diseases. Available in both research and medical device forms, Assessa(R) can support both stratification of patients in clinical trials and diagnosis of disease in the clinic.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTSEFEDWFISEEA

(END) Dow Jones Newswires

August 28, 2015 02:02 ET (06:02 GMT)

Phytopharm (LSE:PYM)
過去株価チャート
から 11 2024 まで 12 2024